The organisations have ended development of the BACE1 (beta secretase 1) inhibitor CNP520 – or umibecestat – which was in two phase 2/3 studies in the Alzheimer's Prevention Initiative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback